Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

被引：32
作者：
Katz, Matthew H. G. [1 ]
Pisters, Peter W. T. [1 ]
Lee, Jeffrey E. [1 ]
Fleming, Jason B. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2011年 / 18卷 / 03期
关键词：
EXPERT CONSENSUS STATEMENT; ADENOCARCINOMA; DEFINITIONS; THERAPY;
D O I：
10.1245/s10434-010-1460-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：608 / 610
页数：3
相关论文
共 11 条
  • [1] Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
    Abrams, Ross A.
    Lowy, Andrew M.
    O'Reilly, Eileen M.
    Wolff, Robert A.
    Picozzi, Vincent J.
    Pisters, Peter W. T.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1751 - 1756
  • [2] Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma
    Brown, Kimberly M.
    Siripurapu, Veeriah
    Davidson, Marson
    Cohen, Steven J.
    Konski, Andre
    Watson, James C.
    Li, Tiaynu
    Ciocca, Vince
    Cooper, Harry
    Hoffman, John P.
    [J]. AMERICAN JOURNAL OF SURGERY, 2008, 195 (03) : 318 - 321
  • [3] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
    Callery, Mark P.
    Chang, Kenneth J.
    Fishman, Elliot K.
    Talamonti, Mark S.
    Traverso, L. William
    Linehan, David C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1727 - 1733
  • [4] Chun Y, 2010, ANN SURG ONCOL, V17, pS26
  • [5] Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy
    Evans, Douglas B.
    Erickson, Beth A.
    Ritch, Paul
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (11) : 2803 - 2805
  • [6] Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
    Katz, Matthew H. G.
    Pisters, Peter W. T.
    Evans, Douglas B.
    Sun, Charlotte C.
    Lee, Jeffrey E.
    Fleming, Jason B.
    Vauthey, J. Nicolas
    Abdalla, Eddie K.
    Crane, Christopher H.
    Wolff, Robert A.
    Varadhachary, Gauri R.
    Hwang, Rosa F.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 206 (05) : 833 - 848
  • [7] Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial
    Katz, Matthew H. G.
    Merchant, Nipun B.
    Brower, Steven
    Branda, Megan
    Posner, Mitchell C.
    Traverso, L. William
    Abrams, Ross A.
    Picozzi, Vincent J.
    Pisters, Peter W. T.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (02) : 337 - 344
  • [8] Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma
    Landry, Jerome
    Catalano, Paul J.
    Staley, Charles
    Harris, Wayne
    Hoffman, John
    Talamonti, Mark
    Xu, Natalie
    Cooper, Harry
    Benson, Al B., III
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (07) : 587 - 592
  • [9] Progress for Resectable Cancer? A Population-Based Assessment of US Practices
    Simons, Jessica P.
    Ng, Sing Chau
    McDade, Theodore P.
    Zhou, Zheng
    Earle, Craig C.
    Tseng, Jennifer F.
    [J]. CANCER, 2010, 116 (07) : 1681 - 1690
  • [10] STOKES JB, ANN SURG ON IN PRESS
12